Atrasentan - CAS 173937-91-2
Catalog number: 173937-91-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
Endothelin Receptor
Description:
atrasentan hydrochloride is the orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.
Publictions citing BOC Sciences Products
  • >> More
Synonyms:
US brand name: Xinlay; Code names: (+)-A 127722; ABT-627; A 127722; Xinlay; ABT 627; NSC720763; A-147627.
MSDS:
Inquire
Current Developer:
Abbott Laboratories
1.Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade.
Vaněčková I1, Řezáčová L2, Kuneš J2, Zicha J2. Life Sci. 2016 Jan 14. pii: S0024-3205(16)30020-0. doi: 10.1016/j.lfs.2016.01.020. [Epub ahead of print]
AIMS: Chronic endothelin receptor A (ETA) blockade lowered blood pressure (BP) by decreasing angiotensin-dependent vasoconstriction and attenuating calcium influx. We tested whether the addition of ETA blockade to renin-angiotensin system (RAS) blockade would have further effects on the principal vasoactive systems contributing to BP maintenance in Ren-2 transgenic rats (TGR).
2.Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
Schievink B1, de Zeeuw D1, Smink PA1, Andress D2, Brennan JJ2, Coll B2, Correa-Rotter R3, Hou FF4, Kohan D5, Kitzman DW6, Makino H7, Parving HH8, Perkovic V9, Remuzzi G10, Tobe S11, Toto R12, Hoekman J13, Lambers Heerspink HJ14. Eur J Prev Cardiol. 2016 May;23(7):758-68. doi: 10.1177/2047487315598709. Epub 2015 Jul 30.
BACKGROUND: A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical trial in Japan (RADAR/JAPAN)) showed that the endothelin A receptor antagonist atrasentan lowers albuminuria, blood pressure, cholesterol, hemoglobin, and increases body weight in patients with type 2 diabetes and nephropathy. We previously developed an algorithm, the Parameter Response Efficacy (PRE) score, which translates short-term drug effects into predictions of long-term effects on clinical outcomes.
3.A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
Qi P1, Chen M2, Zhang LX3, Song RX4, He ZH5, Wang ZP4. PLoS One. 2015 Jul 20;10(7):e0133803. doi: 10.1371/journal.pone.0133803. eCollection 2015.
BACKGROUND: Endothelin A (ET-A) receptor antagonists including zibotentan and atrasentan, have been suggested as a treatment for castration-resistant prostate cancer (CRPC). Our aim was to conduct a meta-analysis and indirect comparison to assess the efficacy and safety of ET-A receptor antagonists for treatment of CRPC.
4.Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy.
Kang WL1,2, Xu GS3. Sci Rep. 2016 Jan 27;6:19979. doi: 10.1038/srep19979.
Atrasentan is a promising therapy for treating diabetic nephropathy (DN). Here we evaluated whether atrasentan down-regulated the miR-199b-5p expression, thereby increasing klotho and preventing renal tubular injury in DN. One-hundred patients with type 2 diabetes mellitus (T2DM) and 40 healthy subjects were included. A DN mice model was established by an injection of streptozotocin (STZ). Human renal proximal tubular epithelial HK-2 cells were exposed to high glucose (20 mmol/L). Treated the mice and HK-2 cells with atrasentan, and we then investigated whether and how miR-199b-5p and Klotho were involved in preventing renal tubular injury in DN. In patients, the serum miR-199b-5p level increased and the klotho concentration decreased in accordance with elevated albuminuria. Atrasentan down-regulated miR-199b-5p and up-regulated klotho of the DN mice and HK-2 cells exposed to high glucose. High glucose promoted the binding of histone H3 to the miR-199b-5p promoter, and atrasentan canceled this effect.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Endothelin Receptor Products


CAS 180384-57-0 Tezosentan

Tezosentan
(CAS: 180384-57-0)

Tezosentan, also known as RO 610612 and Veletri, is a potent dual endothelian (ETA/ETB) receptor antagonist optimized from Bosentan (B675900). It acts as a vaso...

CAS 184036-34-8 Sitaxsentan

Sitaxsentan
(CAS: 184036-34-8)

Sitaxsentan, also called as IPI 1040 or TBC 11251, is a potent orally bioactive ET receptor antagonist that has a long duration of action (t1/2, 5–7 hours) and ...

CAS 195733-43-8 Atrasentan hydrochloride

Atrasentan hydrochloride
(CAS: 195733-43-8)

Atrasentan hydrochloride is the hydrochloride salt form of Atrasentan. Atrasentan, also called as ABT-627, is a selective and orally available antagonist of ETA...

CAS 157380-72-8 TAK-044

TAK-044
(CAS: 157380-72-8)

Tak-044 has been found to be an endothelin receptor antagonist that was once studied against some sort of liver disorders and subarachnoid haemorrhage.

BMS 182874 Hydrochloride
(CAS: 1215703-04-0)

This active molecular is a selective non-peptide Endothelin ETA receptor antagonist. It displays more than 1000-fold selectivity over ETB receptors (Ki of 48 nM...

BMS-193884
(CAS: 176960-47-7)

BMS-193884, an oxazol derivative, has been found to be an endothelin A receptor antagonist and was once studied in the treatmen of heart failure.

CAS 221246-12-4 Fandosentan potassium

Fandosentan potassium
(CAS: 221246-12-4)

Fandosentan potassium is an endothelin A antagonist developed for the treatment of pulmonary hypertension.

CAS 169545-27-1 IRL-2500

IRL-2500
(CAS: 169545-27-1)

IRL-2500, an indol derivative, has been found to be an endothelin B receptor antagonist that was once studied in hypertension.

CAS 117399-94-7 Endothelin 1 swine, human

Endothelin 1 swine, human
(CAS: 117399-94-7)

Endothelin 1 (swine, human), a vasoconstrictor increased in plasma and explants of patients with uterine leiomyomas, is a synthetic peptide with the sequence of...

CAS 210891-04-6 Edonentan

Edonentan
(CAS: 210891-04-6)

Edonentan, also known as BMS-207940, is a very potent and selective ETA endothelin receptor antagonist (Ki= 10 pM) that shows 80000-fold selective for ETA vs ET...

Sparsentan
(CAS: 254740-64-2)

Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.

CAS 157212-55-0 Bosentan Hydrate

Bosentan Hydrate
(CAS: 157212-55-0)

Bosentan inhibits the presser response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity.

A-192621
(CAS: 195529-54-5)

A-192621 is a selective antagonist at endothelin ETB receptor with more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmente...

SB-209670
(CAS: 157659-79-5)

SB-209670 has been found to be an endothelin receptor antagonist that was once studied against arrhythmias and hypertension.

Enrasentan
(CAS: 167256-08-8)

Enrasentan, an indene derivative, has been found to be an endothelin receptor antagonist that was once studied in reperfusion injury and heart failure therapy.

BMS-187308
(CAS: 153624-15-8)

BMS-187308, a sulfonamide derivative, has been found to be an endothelin-A (ETA) antagonist that was once studied about its activity against pressor effect in r...

BMS-248360
(CAS: 254737-87-6)

BMS-248360 is a first orally active generation dual action receptor antagonist. BMS-248360 antagonized both Ang II AT1 and endothelin ETA receptors (AT1 IC50 = ...

CAS 186497-07-4 Zibotentan (ZD4054)

Zibotentan (ZD4054)
(CAS: 186497-07-4)

Zibotentan (ZD4054)is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM).

CAS 180384-56-9 Clazosentan

Clazosentan
(CAS: 180384-56-9)

Clazosentan, also called as AXV 034, Ro 61-1790 or VML 588, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain inj...

CAS 156161-89-6 BQ 788 sodium salt

BQ 788 sodium salt
(CAS: 156161-89-6)

BQ 788 sodium salt is a potent, selective ETB receptor antagonist (IC50 = 1.2 nM) without significant activity on ETA receptor (IC50= 1300 nM).

Chemical Structure

CAS 173937-91-2 Atrasentan

Quick Inquiry

Verification code

Featured Items